- Home
- LFAC vs SGMT Comparison
LFAC vs SGMT Comparison
Compare LFAC & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | LFAC | SGMT |
|---|---|---|
| Founded | 2025 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 195.0M | 169.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LFAC | SGMT |
|---|---|---|
| Price | $9.90 | $4.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $26.38 |
| AVG Volume (30 Days) | 16.4K | ★ 308.8K |
| Earning Date | 01-01-0001 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4,523.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.54 | $1.73 |
| 52 Week High | $10.01 | $11.41 |
Technical Indicators
Market Signals| Indicator | LFAC | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 40.14 | 36.09 |
| Support Level | $9.54 | N/A |
| Resistance Level | $9.97 | $6.62 |
| Average True Range (ATR) | 0.03 | 0.27 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 83.91 | 14.28 |
Price Performance
Historical ComparisonAbout LFAC Leapfrog Acquisition Corporation Class A Ordinary Shares
Leapfrog Acquisition Corp is a blank check company engaged in effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.